Dementia and neurocognitive disorders最新文献

{"title":"Relationship between Lower Urinary Tract Dysfunction and Dementia.","authors":"Hae Ri Na,&nbsp;Sung Tae Cho","doi":"10.12779/dnd.2020.19.3.77","DOIUrl":"https://doi.org/10.12779/dnd.2020.19.3.77","url":null,"abstract":"<p><p>Lower urinary tract dysfunction (LUTD) is a common health challenge in dementia patients with significant morbidity and socioeconomic burden. It often causes lower urinary tract (LUT) symptoms, restricts activities of daily life, and impairs quality of life. Among several LUT symptoms, urinary incontinence (UI) is the most prominent storage symptom in the later stages of dementia. UI in patients with dementia results not only from cognitive impairment, but also from urological defects such as detrusor overactivity. Management of LUTD in patients with dementia is based on multiple factors, including cognitive state, functional impairment, concurrent comorbidities, polypharmacy and urologic condition. Behavioral therapy under caregiver support represents appropriate treatment strategy for UI in these patients. Pharmacological treatment can be considered in patients refractory to behavioral therapy, but it is more effective when combined with behavioral therapy. Antimuscarinics and mirabegron, a beta-3 receptor agonist, are effective for managing storage symptoms involving the LUT. However, anticholinergic side effects in elderly subjects are a concern, particularly when there is a risk of exacerbating cognitive impairment with prolonged use of antimuscarinics. Proper recognition and treatment of LUTD in dementia can improve quality of life in these patients.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"19 3","pages":"77-85"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7f/fc/dnd-19-77.PMC7521953.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38428200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence Approaches to Social Determinants of Cognitive Impairment and Its Associated Conditions.","authors":"Kwang Sig Lee,&nbsp;Kun Woo Park","doi":"10.12779/dnd.2020.19.3.114","DOIUrl":"https://doi.org/10.12779/dnd.2020.19.3.114","url":null,"abstract":"<p><strong>Background and purpose: </strong>This study uses an artificial-intelligence model (recurrent neural network) for evaluating the following hypothesis: social determinants of disease association in a middle-aged or old population are different across gender and age groups. Here, the disease association indicates an association among cerebrovascular disease, hearing loss and cognitive impairment.</p><p><strong>Methods: </strong>Data came from the Korean Longitudinal Study of Ageing (2014-2016), with 6,060 participants aged 53 years or more, that is, 2,556 men, 3,504 women, 3,640 aged 70 years or less (70-), 2,420 aged 71 years or more (71+). The disease association was divided into 8 categories: 1 category for having no disease, 3 categories for having 1, 3 categories for having 2, and 1 category for having 3. Variable importance, the effect of a variable on model performance, was used for finding important social determinants of the disease association in a particular gender/age group, and evaluating the hypothesis above.</p><p><strong>Results: </strong>Based on variable importance from the recurrent neural network, important social determinants of the disease association were different across gender and age groups: 1) leisure activity for men; 2) parents alive, income and economic activity for women; 3) children alive, education and family activity for 70-; and 4) brothers/sisters cohabiting, religious activity and leisure activity for 70+.</p><p><strong>Conclusions: </strong>The findings of this study support the hypothesis, suggesting the development of new guidelines reflecting different social determinants of the disease association across gender and age groups.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"19 3","pages":"114-123"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/11/40/dnd-19-114.PMC7521952.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38428205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Four-Week, Home-Based, Robot Cognitive Intervention for Patients with Mild Cognitive Impairment: a Pilot Randomized Controlled Trial.","authors":"Eun Hye Lee,&nbsp;Bori R Kim,&nbsp;Hyungho Kim,&nbsp;Soo Hyun Kim,&nbsp;Min Young Chun,&nbsp;Hee Kyung Park,&nbsp;Kee Duk Park,&nbsp;Jee Hyang Jeong,&nbsp;Geon Ha Kim","doi":"10.12779/dnd.2020.19.3.96","DOIUrl":"https://doi.org/10.12779/dnd.2020.19.3.96","url":null,"abstract":"<p><strong>Background and purpose: </strong>Previous studies suggest that cognitive intervention can mitigate the development of dementia in patients with mild cognitive impairment (MCI). However, the previous cognitive intervention was mostly provided as a group session, in which MCI patients sometimes had difficulty in regularly attending sessions or were reluctant to participate in group-based classes. Additionally, experienced instructors for traditional cognitive intervention may be unavailable in some chronic-care facilities or community centers. Considering these reasons, we have developed 5 programs for home-based cognitive intervention using a personal robot for MCI patients. In this preliminary study, we aimed to demonstrate the effects of our newly developed home-based cognitive intervention with robots on cognitive function in MCI patients.</p><p><strong>Methods: </strong>We conducted a single-blind randomized controlled trial enrolling 46 MCI patients. Participants were randomized into 2 groups: the robot cognitive intervention (robot) (<i>n</i>=24) group and without cognitive intervention (control) (<i>n</i>=22) group. The interventions comprised 60-min sessions per day for 4 weeks. The primary outcome was the change in cognitive function measured using the Cambridge Neuropsychological Test Automated Battery.</p><p><strong>Results: </strong>There were no significant baseline demographic or clinical differences between the robot and control groups. After the 4-week cognitive intervention, the robot group showed greater improvement in working memory than did the control group.</p><p><strong>Conclusions: </strong>Our home-based cognitive intervention with a personal robot improved the working memory in MCI patients. Further studies with larger samples and longer study periods are required to demonstrate the effects of these programs in other cognitive domains in MCI patients.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"19 3","pages":"96-107"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7c/2c/dnd-19-96.PMC7521954.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38428203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Home-Visiting Cognitive Intervention for the Community-Dwelling Elderly Living Alone.","authors":"Juyoun Lee,&nbsp;Ae Young Lee","doi":"10.12779/dnd.2020.19.2.65","DOIUrl":"https://doi.org/10.12779/dnd.2020.19.2.65","url":null,"abstract":"<p><strong>Background and purpose: </strong>The elderly living alone feel lonelier and more isolated than do those live with others, and they are at higher risk for cognitive decline and depression. This study aimed to assess whether a home-visiting cognitive intervention (HCI) can have positive effects on cognitive improvement for the elderly who living alone.</p><p><strong>Methods: </strong>HCI was conducted from April 2016 to November 2019. Every elder who lived alone and 2 matched partners met for 8 weeks once a week. The partners visited participants' home and did the HCI which composed of cognitive training and cognitive stimulation activities. The Mini-Mental State Examination-dementia screening (MMSE), Geriatric Depression Scale (GDS), the Korean version of instrumental activities of daily living (K-IADL), and the Social Support Scale (SSS) were evaluated before and after HCI to compare the effect of HCI.</p><p><strong>Results: </strong>A total of 258 participants showed significant improvements in MMSE, GDS, K-IADL, and SSS. The MMSE and GDS scores were significantly improved after HCI in both the normal cognition (NC, <i>n</i>=210) and cognitive impairment (CI, <i>n</i>=48) groups. The cognitive effect of HCI for CI was higher than for NC. Among the NC, the magnitude of cognitive improvement was greater in the higher educated group (above 7 years) than in the other groups.</p><p><strong>Conclusions: </strong>Active cognitive interventions could provide possible benefits to improve cognition, emotion, and functional abilities. Regular cognitive-care services like HCI are necessary to reduce dementia risk for the elderly who live alone in the community.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"19 2","pages":"65-73"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1e/3e/dnd-19-65.PMC7326612.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38099268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Aspects of Neurobehavioral Symptoms of Dementia.","authors":"YoungSoon Yang,&nbsp;Nagaendran Kandiah,&nbsp;SangYun Kim,&nbsp;Yong Tae Kwak","doi":"10.12779/dnd.2020.19.2.54","DOIUrl":"https://doi.org/10.12779/dnd.2020.19.2.54","url":null,"abstract":"<p><p>Neurobehavioral symptoms of dementia (NBSD) are very common and are significant symptoms of the illness, contributing most to caregiver burdens and often resulting in premature institutionalization of the person with dementia. The main symptoms of NBSD are anxiety, depression, delusions, and hallucinations. NBSD produce significant problems for both patients and caregivers. The pathophysiology of NBSD is determined by genetic, structural, or environmental factors. Therefore, treatment of NBSD requires continuous and organic cooperation between patients, caregivers, social environments, and doctors. Therefore, it is important for neurologists, who mainly view NBSD for dementia patients, to increase their understanding of these more comprehensive areas as well as the latest insights and treatments to help patients and caregivers.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"19 2","pages":"54-64"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f7/f1/dnd-19-54.PMC7326614.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38099267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amyloid Depositions and Small Vessel Disease in Patients with Cerebral Amyloid Angiopathy: a Case Series.","authors":"Yun Jeong Hong,&nbsp;Si Baek Lee,&nbsp;Seong Hoon Kim,&nbsp;Dong Woo Ryu,&nbsp;Yongbang Kim,&nbsp;Jeong Wook Park","doi":"10.12779/dnd.2020.19.2.74","DOIUrl":"https://doi.org/10.12779/dnd.2020.19.2.74","url":null,"abstract":"Cerebral amyloid angiopathy (CAA) is characterized by cerebrovascular amyloid depositions and amyloidosis-related vasculopathies.1 In the elderly, CAA is a common cause of spontaneous intracerebral hemorrhage (ICH) and associated with Alzheimer's disease (AD).2 Despite increased amyloid positron emission tomography (PET) capabilities, it is not yet well established if amyloid PET can confirm amyloid-driven vasculopathies and CAA.1-3","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"19 2","pages":"74-76"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/d8/dnd-19-74.PMC7326613.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38099269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Executive Summary of the 2019 International Conference of Korean Dementia Association: Exploring the Novel Concept of Alzheimer's Disease and Other Dementia: a Report from the Academic Committee of the Korean Dementia Association.","authors":"Kee Hyung Park,&nbsp;Jae Sung Lim,&nbsp;Sang Won Seo,&nbsp;Yong Jeong,&nbsp;Young Noh,&nbsp;Seong Ho Koh,&nbsp;Jae Sung Bae,&nbsp;Sun Ah Park,&nbsp;Soh Jeong Yang,&nbsp;Hee Jin Kim,&nbsp;Juhee Chin,&nbsp;Jee Hoon Roh,&nbsp;Seong Soo A An","doi":"10.12779/dnd.2020.19.2.39","DOIUrl":"https://doi.org/10.12779/dnd.2020.19.2.39","url":null,"abstract":"<p><p>Because of repeated failures of clinical trials, the concept of Alzheimer's disease (AD) has been changing rapidly in recent years. As suggested by the National Institute on Aging and the Alzheimer's Association Research Framework, the diagnosis and classification of AD is now based on biomarkers rather than on symptoms, allowing more accurate identification of proper candidates for clinical trials by pathogenesis and disease stage. Recent development in neuroimaging has provided a way to reveal the complex dynamics of amyloid and tau in the brain <i>in vivo</i>, and studies of blood biomarkers are taking another leap forward in diagnosis and treatment of AD. In the field of basic and translational research, the development of animal models and a deeper understanding of the role of neuroinflammation are taking a step closer to clarifying the pathogenesis of AD. Development of big data and the Internet of Things is also incorporating dementia care and research into other aspects. Large-scale genetic research has identified genetic abnormalities that can provide a foundation for precision medicine along with the aforementioned digital technologies. Through the first international conference of the Korean Dementia Association, experts from all over the world gathered to exchange opinions with association members on these topics. The Academic Committee of the Korean Dementia Association briefly summarizes the contents of the lectures to convey the depth of the conference and discussions. This will be an important milestone in understanding the latest trends in AD's pathogenesis, diagnostic and therapeutic research and in establishing a future direction.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"19 2","pages":"39-53"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ee/8e/dnd-19-39.PMC7326615.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38098848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of a Patient Who Presented with Rapidly Progressive Dementia and Capricious RT-QuIC Results.","authors":"Eunjoo Rhee,&nbsp;Sung Eun Chung,&nbsp;Hyung Ji Kim,&nbsp;Jae Hong Lee","doi":"10.12779/dnd.2020.19.1.36","DOIUrl":"https://doi.org/10.12779/dnd.2020.19.1.36","url":null,"abstract":"Creutzfeldt-Jakob disease (CJD) is the most common prion disease in humans. Once formed by unknown cause, PrPsc can make the normal cellular PrP (PrPc) transform into the pathogenic PrPsc in a cascade. Consequent extensive neuronal loss causes dementia, involuntary movement, psychosis, and incoordination. The criteria for clinical diagnosis include cerebrospinal fluid (CSF) biomarkers (e.g., 14-3-3 protein and t-tau), specific magnetic resonance image (MRI) finding, electroencephalography (EEG), and clinical symptoms.1 Recently, in vitro protein misfolding amplification system, the real-time quakinginduced conversion assay (RT-QuIC), for the detection of PrPsc in CSF was developed and showed ultra-high sensitivity and specificity, amending the diagnostic criteria.2 Here, we report the case of a patient without obvious clinical symptoms of sporadic Creutzfeldt-Jakob disease (sCJD) except rapidly progressive cognitive decline and a positive RT-QuIC assay who was not CJD.","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"19 1","pages":"36-38"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f1/77/dnd-19-36.PMC7105714.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37740478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood.","authors":"HeeYang Lee,&nbsp;Daniella Ugay,&nbsp;Seungpyo Hong,&nbsp;YoungSoo Kim","doi":"10.12779/dnd.2020.19.1.1","DOIUrl":"https://doi.org/10.12779/dnd.2020.19.1.1","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is pathologically characterized by a long progressive phase of neuronal changes, including accumulation of extracellular amyloid-β (Aβ) and intracellular neurofibrillary tangles, before the onset of observable symptoms. Many efforts have been made to develop a blood-based diagnostic method for AD by incorporating Aβ and tau as plasma biomarkers. As blood tests have the advantages of being highly accessible and low cost, clinical implementation of AD blood tests would provide preventative screening to presymptomatic individuals, facilitating early identification of AD patients and, thus, treatment development in clinical research. However, the low concentration of AD biomarkers in the plasma has posed difficulties for accurate detection, hindering the development of a reliable blood test. In this review, we introduce three AD blood test technologies emerging in South Korea, which have distinctive methods of heightening detection sensitivity of specific plasma biomarkers. We discuss in detail the multimer detection system, the self-standard analysis of Aβ biomarkers quantified by interdigitated microelectrodes, and a biomarker ratio analysis comprising Aβ and tau.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"19 1","pages":"1-18"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/7b/dnd-19-1.PMC7105719.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37740477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determining the Neurocognitive Status and the Functional Ability of Patients to Screen for HIV-Associated Neurocognitive Disorder (HAND).","authors":"Ritika Agarwal,&nbsp;Ravinder Singh Aujla,&nbsp;Amit Gupta,&nbsp;Mukesh Kumar","doi":"10.12779/dnd.2020.19.1.19","DOIUrl":"https://doi.org/10.12779/dnd.2020.19.1.19","url":null,"abstract":"<p><strong>Background and purpose: </strong>To adequately evaluate the extent of neurocognitive impairment in patient living with human immunodeficiency virus (PLHIV), a battery of neuropsychological tests is typically administered which are neither cost effective nor time efficient in the outpatient clinical setting. The aim of the study was to assess neurocognitive status and functional ability of people living with HIV and find a brief screening tool to identify those who would benefit from a full diagnostic evaluation.</p><p><strong>Methods: </strong>The study enrolled 160 PLHIV (80 pre-antiretroviral therapy [ART] and 80 on ART) fulfilling the inclusion and exclusion criteria. Neurocognitive assessment and an assessment of Functional ability was done by using the Montreal Cognitive Assessment (MoCA) and Lawton and Brody Instrumental Activities of Daily Living Scale scale, respectively.</p><p><strong>Results: </strong>The study population consisted of 75.6% males and 24.4% females with mean age of 44±10 years. The overall prevalence of HIV associated neurocognitive disorder (HAND) in the study subjects was 52.5%. Of these, 47.5% had asymptomatic neurocognitive impairment and 5% had minor neurocognitive disorder. In MoCA, the most frequently affected domains were Language (97.6%), visuospatial ability (92.9%) and memory (71.4%).</p><p><strong>Conclusions: </strong>The prevalence of HAND in both groups were similar suggesting that neurocognitive impairment starts early in HIV infection. Memory and Visuospatial function impairment had the most predictive potential for detecting the presence of HAND. HAND screening is recommended in all PLHIV at enrolment into care. Simple tools like MoCA can be used in busy outpatient settings by healthcare workers to screen for HAND.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":"19 1","pages":"19-27"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/81/6d/dnd-19-19.PMC7105717.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37740473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}